Register for our free email digests:
Division of Gilead Sciences Inc.
Latest From China Kanghui Holdings
Once a lesser known firm in US life sciences investing, Vivo Capital has emerged as a global leader in biopharmaceutical and medtech start-ups, raising a $750 million fund that will be invested in the US, Europe, and China.
Despite a well-tailored product lineup targeting the value market segment being high on top medical device executives’ minds, a more sophisticated commercial model will help win the day in China. In effect, a key shift away from fast sales force expansion towards sophistication and specialization is emerging in the country, notes a new McKinsey study.
Becton Dickinson has been growing north of 20% several years in a row in China, which has now overtaken Japan to become the U.S. firm’s second largest market. Local needs-based product customization and innovation, and commercial partnerships with national players win the day, says Becton Dickinson China general manager James Deng in an exclusive interview.
Medtronic is expanding its alliance with Lifetech in China to develop and locally manufacture pacemakers for the Chinese market. The deal will strengthen Medtronic’s presence in pacemakers and put pressure on others like the Microport/Sorin JV, which is looking for expansion in this market.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Gilead Sciences Inc.
- Senior Management
Martin Bonde, CEO
Henrik Blou, Dir., Bus. Dev.
Lars-Ole Gerlach, EVP, R&D
- Contact Info
Phone: (45) 2025 3560
Ole Maaløesvej 3
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.